Production (Stage)
Silence Therapeutics plc
SLN
$5.19
$0.193.80%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -14.41% | 41.45% | -41.96% | -36.76% | 16.74% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -14.41% | 41.45% | -41.96% | -36.76% | 16.74% |
| Cost of Revenue | -5.72% | -4.16% | -28.43% | -41.46% | -37.91% |
| Gross Profit | -18.15% | 72.79% | -53.24% | -32.56% | 87.90% |
| SG&A Expenses | 16.05% | 6.56% | 4.84% | -1.63% | 0.04% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 37.33% | 12.34% | -11.62% | -24.05% | -19.02% |
| Operating Income | -79.86% | 5.08% | -6.33% | 16.44% | 35.31% |
| Income Before Tax | -81.30% | 15.71% | -16.19% | 22.44% | 36.21% |
| Income Tax Expenses | -42.35% | 140.29% | 131.34% | 144.22% | 148.94% |
| Earnings from Continuing Operations | -68.72% | 12.33% | -43.35% | 0.15% | 16.70% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -68.72% | 12.33% | -43.35% | 0.15% | 16.70% |
| EBIT | -79.86% | 5.08% | -6.33% | 16.44% | 35.31% |
| EBITDA | -81.11% | 5.12% | -6.33% | 16.70% | 35.73% |
| EPS Basic | -35.95% | 30.20% | -16.36% | 14.65% | 26.31% |
| Normalized Basic EPS | -44.64% | 33.52% | 7.84% | 34.57% | 42.93% |
| EPS Diluted | -35.95% | 30.20% | -16.36% | 14.65% | 26.31% |
| Normalized Diluted EPS | -44.64% | 33.52% | 7.84% | 34.57% | 42.93% |
| Average Basic Shares Outstanding | 20.41% | 24.68% | 21.50% | 18.36% | 15.99% |
| Average Diluted Shares Outstanding | 20.41% | 24.68% | 21.50% | 18.36% | 15.99% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |